 <h1>Increlex Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>mecasermin</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about mecasermin. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Increlex.</p><h2>In Summary</h2><p><b>Common side effects of Increlex include:</b> tonsil disease.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to mecasermin: subcutaneous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, mecasermin (the active ingredient contained in Increlex) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking mecasermin:</p><p>
<i>More common</i>
</p><ul>
<li>Anxiety</li>
<li>bluish skin color of the fingertips</li>
<li>blurred vision</li>
<li>breathlessness</li>
<li>chest pain</li>
<li>chills</li>
<li>cold sweats</li>
<li>coma</li>
<li>confusion</li>
<li>cool, pale skin</li>
<li>depression</li>
<li>dizziness</li>
<li>fast heartbeat</li>
<li>headache</li>
<li>increased hunger</li>
<li>loss of hearing</li>
<li>nausea</li>
<li>nervousness</li>
<li>nightmares</li>
<li>rapid growth of normal cells of the thymus (no symptoms)</li>
<li>seizures</li>
<li>shakiness</li>
<li>slurred speech</li>
<li>thickening of the skin</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Change in the ability to see colors, especially blue or yellow</li>
<li>cough</li>
<li>difficult or labored breathing</li>
<li>difficulty with swallowing</li>
<li>hives or welts, itching, or skin rash</li>
<li>itching or hives at the injection site</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>limp</li>
<li>pain in the hip or knee</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>redness of the skin</li>
<li>tightness in the chest</li>
<li>vomiting</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking mecasermin:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Anxiety</li>
<li>arm or leg pain</li>
<li>backache</li>
<li>changes in vision</li>
<li>excessive sweating</li>
<li>extreme weakness</li>
<li>frequent urination</li>
<li>increase in hands and feet size</li>
<li>increased thirst</li>
<li>increased volume of pale, diluted urine</li>
<li>joint pain</li>
<li>stop in menstruation</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of mecasermin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Abnormal response of the tympanic membrane to air pressure</li>
<li>difficulty with moving</li>
<li>difficulty with swallowing</li>
<li>ear pain</li>
<li>earache</li>
<li>large, flat, blue or purplish patches in the skin</li>
<li>muffled hearing</li>
<li>muscle pain or stiffness</li>
<li>redness or swelling in the ear</li>
<li>sense of fullness in the ear</li>
<li>snoring</li>
<li>sore throat</li>
<li>voice changing</li>
</ul><p>
<!-- end subcutaneous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to mecasermin: subcutaneous solution</i></p><h3>General</h3><p>The most common adverse events were hypoglycemia, injection site hypertrophy, snoring, hypoacusis, headache, and tonsillar hypertrophy.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypoglycemia (47%)</p>
<p><b>Common</b> (1% to 10%): Hypoglycemic seizure, hyperglycemia, hyperlipidemia, obesity, increased weight<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection site hypertrophy (32%)</p>
<p><b>Common</b> (1% to 10%): Injection site pain, injection site bruising, injection site fibrosis, injection site reaction, injection site swelling, injection site induration, injection site pigmentation changes </p>
<p><b>Postmarketing reports</b>: Pruritus, urticaria, injection site reactions (e.g.  erythema, pain, hematoma, hemorrhage, induration, rash, swelling)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Hypoacusis (20%), febrile infection, otitis media, serous otitis media, chronic otitis media serous, otitis externa, ear infection</p>
<p><b>Common</b> (1% to 10%): Fluid in middle ear, ear pain, abnormal tympanometry, ear tube insertion, otorrhea, ear disorder, middle ear disorder, tympanic membrane disorder, ear congestion, Mucosal membrane hyperplasia, hypertrophy, mucosal edema, asthenia, chest discomfort, abnormal tympanometry, adenotonsillectomy, adenoidectomy, ear tube insertion</p>
<p><b>Frequency not reported</b>: Elevations in cholesterol, elevations in triglycerides<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Snoring (22%), tonsillar hypertrophy (16%), upper respiratory tract infection, pharyngitis, tonsillitis</p>
<p><b>Common</b> (1% to 10%): Tonsillectomy/adenoidectomy, obstructive sleep apnea, adenoidal hypertrophy, nasal turbinate hypertrophy, dyspnea, nasal mucosal disorder, obstructive airway disorder, abnormal respiration, nasal congestion, mouth breathing<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (18%)</p>
<p><b>Common</b> (1% to 10%): Intracranial hypertension, dizziness, convulsions, febrile convulsion, benign intracranial hypertension, loss of consciousness, sleep apnea syndrome, dizziness, tremor, restless leg syndrome, lethargy<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Anti-IGF-1 antibodies (up to 61%), thymus hypertrophy<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Cardiac murmur, cardiomegaly, ventricular hypertrophy, atrial hypertrophy, tachycardia, tachycardia paroxysmal, mitral valve incompetence, tricuspid valve incompetence, abnormal echocardiogram</p>
<p><b>Frequency not reported</b>: Cardiomegaly/valvulopathy<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Tonsillar hypertrophy appears to occur more frequently in the first 1 to 2 years of therapy with lesser tonsillar growth in subsequent years.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Oral candidiasis</p>
<p><b>Common</b> (1% to 10%): Vomiting, retching, abdominal pain, upper abdominal pain, abdominal distension, dysphagia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Lipohypertrophy, bruising, skin hypertrophy, acrochordons, abnormal hair texture, pigmented nevus</p>
<p><b>Frequency not reported</b>: Thickening of the soft tissues of the face</p>
<p><b>Postmarketing reports</b>: Alopecia, hair texture abnormal<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased alanine aminotransferase, increased aspartate aminotransferase</p>
<p><b>Frequency not reported</b>: Elevated AST, elevated LDH, elevated ALT<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Local and/or systemic hypersensitivity</p>
<p><b>Postmarketing reports</b>: Anaphylaxis, local allergic reactions, generalized urticaria, angioedema, dyspnea<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Lymphadenopathy<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia, pain in extremity, myalgia, scoliosis, spinal deformity, soft tissue disorder, muscle cramp, flank pain, musculoskeletal stiffness, congenital jaw malformation</p>
<p><b>Postmarketing reports</b>: Osteonecrosis/avascular necrosis (occasionally associated with slipped capital femoral epiphysis)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Nephrolithiasis, hydronephrosis, renal colic</p>
<p><b>Frequency not reported</b>: Renal and splenic length increased rapidly<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Papilledema, reduced visual acuity, myopia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Gynecomastia, ovarian cyst<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, sleep terror, nervousness, abnormal behavior, disorientation<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Increlex (mecasermin)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: insulin-like growth factors</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Increlex &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Primary IGF-1 Deficiency</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to mecasermin: subcutaneous solution</i></p><h3>General</h3><p>The most common adverse events were hypoglycemia, injection site hypertrophy, snoring, hypoacusis, headache, and tonsillar hypertrophy.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypoglycemia (47%)</p><p><b>Common</b> (1% to 10%): Hypoglycemic seizure, hyperglycemia, hyperlipidemia, obesity, increased weight<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection site hypertrophy (32%)</p><p><b>Common</b> (1% to 10%): Injection site pain, injection site bruising, injection site fibrosis, injection site reaction, injection site swelling, injection site induration, injection site pigmentation changes </p><p><b>Postmarketing reports</b>: Pruritus, urticaria, injection site reactions (e.g.  erythema, pain, hematoma, hemorrhage, induration, rash, swelling)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Hypoacusis (20%), febrile infection, otitis media, serous otitis media, chronic otitis media serous, otitis externa, ear infection</p><p><b>Common</b> (1% to 10%): Fluid in middle ear, ear pain, abnormal tympanometry, ear tube insertion, otorrhea, ear disorder, middle ear disorder, tympanic membrane disorder, ear congestion, Mucosal membrane hyperplasia, hypertrophy, mucosal edema, asthenia, chest discomfort, abnormal tympanometry, adenotonsillectomy, adenoidectomy, ear tube insertion</p><p><b>Frequency not reported</b>: Elevations in cholesterol, elevations in triglycerides<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Snoring (22%), tonsillar hypertrophy (16%), upper respiratory tract infection, pharyngitis, tonsillitis</p><p><b>Common</b> (1% to 10%): Tonsillectomy/adenoidectomy, obstructive sleep apnea, adenoidal hypertrophy, nasal turbinate hypertrophy, dyspnea, nasal mucosal disorder, obstructive airway disorder, abnormal respiration, nasal congestion, mouth breathing<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (18%)</p><p><b>Common</b> (1% to 10%): Intracranial hypertension, dizziness, convulsions, febrile convulsion, benign intracranial hypertension, loss of consciousness, sleep apnea syndrome, dizziness, tremor, restless leg syndrome, lethargy<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Anti-IGF-1 antibodies (up to 61%), thymus hypertrophy<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Cardiac murmur, cardiomegaly, ventricular hypertrophy, atrial hypertrophy, tachycardia, tachycardia paroxysmal, mitral valve incompetence, tricuspid valve incompetence, abnormal echocardiogram</p><p><b>Frequency not reported</b>: Cardiomegaly/valvulopathy<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Tonsillar hypertrophy appears to occur more frequently in the first 1 to 2 years of therapy with lesser tonsillar growth in subsequent years.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Oral candidiasis</p><p><b>Common</b> (1% to 10%): Vomiting, retching, abdominal pain, upper abdominal pain, abdominal distension, dysphagia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Lipohypertrophy, bruising, skin hypertrophy, acrochordons, abnormal hair texture, pigmented nevus</p><p><b>Frequency not reported</b>: Thickening of the soft tissues of the face</p><p><b>Postmarketing reports</b>: Alopecia, hair texture abnormal<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased alanine aminotransferase, increased aspartate aminotransferase</p><p><b>Frequency not reported</b>: Elevated AST, elevated LDH, elevated ALT<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Local and/or systemic hypersensitivity</p><p><b>Postmarketing reports</b>: Anaphylaxis, local allergic reactions, generalized urticaria, angioedema, dyspnea<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Lymphadenopathy<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia, pain in extremity, myalgia, scoliosis, spinal deformity, soft tissue disorder, muscle cramp, flank pain, musculoskeletal stiffness, congenital jaw malformation</p><p><b>Postmarketing reports</b>: Osteonecrosis/avascular necrosis (occasionally associated with slipped capital femoral epiphysis)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Nephrolithiasis, hydronephrosis, renal colic</p><p><b>Frequency not reported</b>: Renal and splenic length increased rapidly<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Papilledema, reduced visual acuity, myopia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Gynecomastia, ovarian cyst<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, sleep terror, nervousness, abnormal behavior, disorientation<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Increlex (mecasermin)." Tercica Inc, Brisbane, CA. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about Increlex (mecasermin)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: insulin-like growth factors</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Increlex &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Primary IGF-1 Deficiency</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>